US Patent and Trademark Office Director Kathi Vidal ordered additional review of a tribunal decision denying SynAffix B.V.'s petition to cancel a patent covering conjugates for targeted delivery of drugs to specific cells.
The director instructed a recently created Patent Office rehearing panel on Thursday to take a second look at the Patent Trial and Appeal Board’s August decision denying the biotechnology company’s request to review Hangzhou DAC Biotechnology Co. Ltd.'s US Patent No. 10,131,682, which relates to a substance that can purportedly increase the potency of cancer treatment.
SynAffix requested director review in September. It argued that the ...
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.